[Persistent value of intra-arterial fibrinolysis 8 hours or more following central retinal artery occlusion or of its branches]

J Fr Ophtalmol. 1998 Aug-Sep;21(7):466-70.
[Article in French]

Abstract

Purpose: To establish that intra-arterial fibrinolysis of the ophthalmic artery can still be efficient 8 hours or more after a central retinal artery occlusion.

Material and methods: Nine to twenty hours (average 12.5 H) after a loss of vision due to a central retinal artery occlusion or the occlusion of its branches, 7 patients were treated by intra-arterial fibrinolysis. The vision of the affected eye was limited to light perception for four patients, to hand movement at 1 meter for two patients, and to 4/10 P2 for one patient. Under radiological guidance, 300.000 IU of urokinase was injected through a microcatheter placed in the ophthalmic artery (6 patients), or in the facial artery (1 patient); in this case the angiogram showed an occlusion of the internal carotid artery and a retrograde filling of the ophthalmic artery through the facial artery.

Results: We did not observed any complication. The 3 patients who had a vision better than light perception recovered a vision of 10/10 P2. For the others: two patients recovered a vision of 9/10 P2 and 5/10 P2, two did not recover.

Conclusion: Fibrinolysis of the ophthalmic artery must ideally be performed as soon as possible, but a recovery is still possible more than 8 hours after the onset of the loss of vision. The time limit is not yet defined but after 24 hours, the chance of improvement seems to be very low.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Fluorescein Angiography
  • Humans
  • Injections, Intra-Arterial
  • Male
  • Middle Aged
  • Ophthalmic Artery
  • Retinal Artery Occlusion / drug therapy*
  • Thrombolytic Therapy*
  • Time Factors
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / administration & dosage*
  • Visual Acuity / drug effects

Substances

  • Urokinase-Type Plasminogen Activator